Marksans Pharma has completed the acquisition of a manufacturing site from Tevapharm India in Plot No. Al, Phase I-A, Verna Industrial Estate, Verna, Goa 403722, India. The acquisition was first announced in October 2022.
With the completion of the acquisition, Marksans will start operating at the acquired facility. As a part of the agreement, Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates,
ensuring high-quality standards. The contract manufacturing agreement with Teva is to continue providing an uninterrupted supply of Teva's important medicines to customers and patients. Marksans has retained
the transferring employees on terms materially similar to its current employment. Teva's adjoining Watson Pharma Private Limited's site is not part of the divestment with Marksans and witt remain with Teva.
The acquired facility will enable Marksans Pharma to potentially double the existing Indian capacity from 8bn units per annum currently. It is a scalable capacity to manufacture oral solid dosage forms. Marksans
plans to manufacture tablets, hard and soft gel capsules, ointments, liquids, and creams, from the new capacity. The manufacturing site is spread across 47,597 square meters and has approvals to manufacture
products from the EU, Health Canada & Japanese Health Authority.
|